NCT03758365 - Evaluation of the Vasoconstriction Properties of MC2-01 Cream | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

November 23, 2018

Study Completion Date

November 23, 2018

Conditions

Vasoconstriction

Interventions

DRUG

MC2-01 Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Clobetasol Propionate 0.05% Lotion

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Betamethasone Dipropionate 0.05% Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Triamcinolone Acetonide 0.1% Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Hydrocortisone Butyrate 0.1% Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Desonide 0.05% Cream

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

DRUG

Vehicle

Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

Trial Locations (1)

CPCAD, Nice